



## Immune Responses to Emerging Viruses

Guest Editor:

**Dr. Yongjun Sui**

National Cancer Institute,  
National Institutes of Health,  
Bethesda, MD, USA

Deadline for manuscript  
submissions:

**closed (20 March 2022)**

### Message from the Guest Editor

Dear Colleagues,

The emergence of novel infectious viruses is a major threat to human health. Viruses including, but not limited to, severe acute respiratory syndrome-coronavirus (SARS-CoV; SARS-CoV-2), Middle East respiratory syndrome-coronavirus (MERS-CoV), Ebola virus (EBOV), Zika virus (ZIKV), and highly pathogenic influenza A viruses (IAVs) have evolved various ways of evading human defense mechanisms.

Much has been learned regarding the emergence and transmission of these viruses. To control the potential pandemic, we need to develop effective vaccines and antiviral therapeutics. The key to this is to deeply understand immune pathogenesis/virus–host interaction, and to identify the immune correlates of protection using in vitro and in vivo models.

We would like to invite you to submit a research article, review, or short communication focused on the investigation of innate, adaptive immune responses, to emerging viruses, as well as any vaccine development or therapeutic strategies to control their spread and transmission to this special issue.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Lawrence S. Young

Warwick Medical School,  
University of Warwick, Coventry  
CV4 7AL, UK

## Message from the Editor-in-Chief

The worldwide impact of infectious disease is incalculable. The consequences for human health in terms of morbidity and mortality are obvious and vast but, when infections of animals and plants are also taken into account, it is hard to imagine any other disease that has such a significant impact on our lives—on healthcare systems, on agriculture and on world economics. *Pathogens* is proud to continue to serve the international community by publishing high quality studies that further our understanding of infection and have meaningful consequences for disease intervention.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PubAg, CaPlus / SciFinder, AGRIS, and other databases.

**Journal Rank:** JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*General Immunology and Microbiology*)

## Contact Us

Pathogens Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pathogens](http://mdpi.com/journal/pathogens)  
[pathogens@mdpi.com](mailto:pathogens@mdpi.com)  
[X@Pathogens\\_MDPI](https://twitter.com/Pathogens_MDPI)